Zambon: Open Accelerator 2018 call for projects

19 April 2018

Helsinn Provides Grant for ESMO’s Preceptorship Programme for Supportive and Palliative Care

12 April 2018

Helsinn Group and Glenmark Pharmaceuticals enter into an exclusive licensing agreement for launch of AKYNZEO® in India and Nepal

4 April 2018

Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced

28 March 2018

Helsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership Awards

26 March 2018

1 Helsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV vs NEPA Oral for the prevention of chemotherapy induced nausea and vomiting (CINV) in Women with Breast Cancer

20 March 2018

Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics (HTU)

28 February 2018

Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement

30 January 2018

US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi® in the US Market Are Invalid

18 January 2018

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)

12 January 2018